Zuardi, A. W., Morais, S. L., Guimaraes, F. S., & Mechoulam, R. (1995). „Antipsychotic effect of cannabidiol” (angol nyelven). Journal of Clinical Psychiatry56 (10), 485–6. o.
Cannabis and Cannabinoids (PDQ®). National Cancer Institute at the National Institutes of Health. National Cancer Institute, 2013. augusztus 2. (Hozzáférés: 2013. augusztus 24.)
Társaság a Szabadságjogokért: Drogjog 1999 (magyar nyelven). daath.hu. (Hozzáférés: 2016. szeptember 3.)
doi.org
dx.doi.org
Aizpurua-Olaizola, O., Soydaner, U., Öztürk, E., Schibano, D., Simsir, Y., Navarro, P., et al. & Usobiaga, A. (2016). „Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes” (angol nyelven). Journal of natural products79 (2), 324–331. o. DOI:10.1021/acs.jnatprod.5b00949. PMID26836472.
Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, Sánchez C, Velasco G, González-Feria L. (2006). „A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme” (angol nyelven). British journal of cancer95 (2), 197-203. o. DOI:10.1038/sj.bjc.6603236. PMID16804518.
Grbic, J., Goddard, P., & Ryder, D. (2017). „Observations of the role of science in the United States medical cannabis state policies: Lessons learnt” (angol nyelven). International Journal of Drug Policy. DOI:10.1016/j.drugpo.2016.12.019. PMID28190671.
Hussain, S. A., Zhou, R., Jacobson, C., Weng, J., Cheng, E., Lay, J., & Sankar, R. (2015). „Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox–Gastaut syndrome.” (angol nyelven). Epilepsy & Behavior47, 138-41.. o. DOI:10.1016/j.yebeh.2015.04.009. PMID25935511.
Silvestro, S., Mammana, S., Cavalli, E., Bramanti, P., & Mazzon, E. (2019). „Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials” (angol nyelven) 24 (8). DOI:10.3390/molecules24081459. PMID31013866.
O'Connell,B. K., Gloss, D., & Devinsky, O. (2017). „Cannabinoids in treatment-resistant epilepsy: a review” (angol nyelven). Epilepsy & Behavior70, 341-348. o. DOI:doi.org/10.1016/j.yebeh.2016.11.012.
Pacula, Rosalie Liccardo, et al. (2014). „Developing public health regulations for marijuana: lessons from alcohol and tobacco” (angol nyelven). Journal Information104 (6), 1021-8.. o. DOI:10.2105/AJPH.2013.301766. PMID24825201.
Calabria, B., Degenhardt, L., Hall, W., & Lynskey, M. (2010). „Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use” (angol nyelven). Drug and alcohol review29 (3), 318-330. o. DOI:10.1111/j.1465-3362.2009.00149.x. PMID20565525.
Thomas, Hue. (1993). „Psychiatric symptoms in cannabis users” (angol nyelven). The British Journal of Psychiatry163 (2), 141-149. o. DOI:10.1192/bjp.163.2.141. PMID8075903.
Laumon, B., Gadegbeku, B., Martin, J. L., & Biecheler, M. B. (2005). „Cannabis intoxication and fatal road crashes in France: population based case-control study” (angol nyelven). Bmj331 (7529), 1371. o. DOI:10.1136/bmj.38648.617986.1F. PMID16321993.
Hesse M., Thylstrup B. (2013). „Time-course of the DSM-5 cannabis withdrawal symptoms in poly-substance abusers” (angol nyelven). BMC psychiatry13 (1), 1. o. DOI:10.1186/1471-244X-13-258. PMID24118963.
Budney, Alan J., and John R. Hughes (2006). „The cannabis withdrawal syndrome” (angol nyelven). Current Opinion in Psychiatry19 (3), 233–238. o. DOI:10.1097/01.yco.0000218592.00689.e5.
Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D. (2013). „The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users” (angol nyelven). Drug and alcohol dependence128 (1), 64-70. o. DOI:10.1016/j.drugalcdep.2012.08.001. PMID22921474.
A.M. Weinstein, David A. Gorelick (2011). „Pharmacological Treatment of Cannabis Dependence” (angol nyelven). Current Pharmaceutical Design17 (14), 1351–1358.. o. DOI:10.2174/138161211796150846.
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., et al. & UK MS research group. (2003). „Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.” (angol nyelven). Lancet362 (9395), 1517-1526. o. DOI:10.1016/S0140-6736(03)14738-1. PMID14615106.
Makela P, Robson P, House H, Bateman C. (2004). „Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.” (angol nyelven). Multiple Sclerosis10 (4), 434-441. o. DOI:10.1191/1352458504ms1082oa. PMID15327042.
Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ. (2005). „Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.” (angol nyelven). J. Neurol. Neurosurg. Psychiatry76 (12), 1664--1669. o. DOI:10.1136/jnnp.2005.070136. PMID16291891.
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., et al. & Rossi, P. (2011). „A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols*(Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis.” (angol nyelven). European Journal of Neurology18 (9), 1122–1131. o. DOI:10.1111/j.1468-1331.2010.03328.x. PMID21362108.
Koppel, B. S., Brust, J. C., Fife, T., Bronstein, J., Youssof, S., Gronseth, G., & Gloss, D. (2014. April). „Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders” (angol nyelven). Neurology82 (17), 1556-1563. o. DOI:10.1212/WNL.0000000000000363.. PMID24778283.
Iskedjian, M., Bereza, B., Gordon, A., Piwko, C., & Einarson, T. R. (2007). „Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.” (angol nyelven). Current medical research and opinion23 (1), 17-24. o. DOI:10.1185/030079906X158066. PMID17257464.
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005). „Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.” (angol nyelven). Neurology65 (6), 812-819. o. DOI:10.1212/01.wnl.0000176753.45410.8b. PMID16186518.
Rog, David J., Turo J. Nurmikko, and Carolyn A. Young. (2007). „Oromucosal Δ 9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.” (angol nyelven). Clinical therapeutics29 (9), 2068-2079. o. DOI:10.1016/j.clinthera.2007.09.013. PMID18035205.
Serpell, Michael G., William Notcutt, and Christine Collin. (2013). „Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.” (angol nyelven). Journal of neurology260 (1), 285-295. o. DOI:10.1007/s00415-012-6634-z. PMID22878432.
Haupts, M., Vila, C., Jonas, A., Witte, K., & Álvarez-Ossorio, L. (2016). „Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC: CBD Oromucosal Spray for Multiple Sclerosis Spasticity.” (angol nyelven). European Neurology75 (5-6), 236-243. o. DOI:10.1159/000445943. PMID27160412.
Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D. (2015). „Neuroprotection in experimental autoimmune encephalomyelitis and progressive multiple sclerosis by cannabis-based cannabinoids.” (angol nyelven). Journal of Neuroimmune Pharmacology10 (2), 281-292. o. DOI:10.1007/s11481-014-9575-8. PMID25537576.
Brady, C. M., DasGupta, R., Dalton, C., Wiseman, O. J., Berkley, K. J., & Fowler, C. J. (2004). „An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.” (angol nyelven). Multiple Sclerosis10 (4), 425-433. o. DOI:10.1191/1352458504ms1063oa. PMID15327041.
Kavia, R. B. C., De Ridder, D., Constantinescu, C. S., Stott, C. G., & Fowler, C. J. (2010). „Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.” (angol nyelven). Multiple Sclerosis16 (11), 1349-1359. o. DOI:10.1177/1352458510378020. PMID20829244.
Mecha, M., Feliú, A., Iñigo, P. M., Mestre, L., Carrillo-Salinas, F. J., & Guaza, C. (2013). „Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A 2A receptors.” (angol nyelven). Neurobiology of disease (59), 141-150. o. DOI:10.1016/j.nbd.2013.06.016. PMID23851307.
Granja, A. G., Carrillo-Salinas, F., Pagani, A., Gómez-Cañas, M., Negri, R., Navarrete, C., Calzado, M. A. (2012). „A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis.” (angol nyelven). Journal of Neuroimmune Pharmacology7 (4), 1002-1016.. o. DOI:10.1007/s11481-012-9399-3. PMID22971837.
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., & Wong, M. (2016). „Cannabidiol for Intractable Epilepsy: Results from the Latest Open-Label Trial” (angol nyelven). The Lancet Neurology15 (3), 270-278.. o. DOI:10.1016/S1474-4422(15)00379-8. PMID26724101.
Gross DW, Hamm J, Ashworth NL, Quigley D. (2014). „Marijuana use and epilepsy Prevalence in patients of a tertiary care epilepsy center” (angol nyelven). Neurology62 (11), 2095-2097.. o. DOI:10.1212/01.WNL.0000127623.03766.75. PMID15184622.
Mathern GW, Beninsig L, Nehlig A. (2015). „Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: Result of Epilepsia's survey” (angol nyelven). Epilepsia56 (1), 1-6. o. DOI:10.1111/epi.12843. PMID25413126.
Alexander SP (2016). „Therapeutic potential of cannabis-related drugs” (angol nyelven). Progress in Neuro-Psychopharmacology and Biological Psychiatry4 (64), 157-166. o. DOI:10.1016/j.pnpbp.2015.07.001. PMID26216862.
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., et al. & Wong, M. (2016). „Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial” (angol nyelven). The Lancet Neurology15 (3), 270-278. o. DOI:10.1016/S1474-4422(15)00379-8. PMID26724101.
Borgelt LM, Franson KL, Nussbaum AM, Wang GS (2013). „The pharmacologic and clinical effects of medical cannabis” (angol nyelven). Pharmacotherapy (Review)33 (2), 195–209. o. DOI:10.1002/phar.1187.. PMID23386598.
Hernandez, F. A., & Chandra, S. B. (2016). „The current state and potential direction of cannabis research” (angol nyelven). Journal of Experimental and Integrative Medicine6 (1), 44-48. o. DOI:10.5455/jeim.310316.rw.014.
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006). „The emerging role of the endocannabinoid system in endocrine regulation and energy balance.” (angol nyelven). Endocrine reviews27 (1), 73-100. o. DOI:10.1210/er.2005-0009. PMID16306385.
Varga, Z., rafay ali Sabzwari, S., & Vargova, V. (2017). „Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue” (angol nyelven). Cureus9 (4). DOI:10.7759/cureus.1144. PMC5422108.
Charlson, Fiona, et al. (2009). „A systematic review of research examining benzodiazepine‐related mortality” (angol nyelven). Pharmacoepidemiology and drug safety18 (2), 93-103.. o. DOI:10.1002/pds.1694. PMID19125401.
Abrams, D. I., & Guzman, M. (2015). „Cannabis in cancer care” (angol nyelven). Clinical Pharmacology & Therapeutics97 (6), 575-586. o. DOI:10.3747/co.23.3099.
Bowles, DW (2012. január 6.). „The intersection between cannabis and cancer in the United States”. Critical reviews in oncology/hematology83 (1), 1–10. o. DOI:10.1016/j.critrevonc.2011.09.008. PMID22019199.
Ma, Chao, et al. Velasco, Guillermo, et al. (2007). „Cannabinoids and gliomas” (angol nyelven). Molecular neurobiology36 (1), 60-67. o. DOI:10.1007/s12035-007-0002-5.
Abrams, D. I. (2016). „Integrating cannabis into clinical cancer care” (angol nyelven). Current Oncology23 (2), S8. o. DOI:10.3747/co.23.3099. PMID27022315.
Pyszniak, M., Tabarkiewicz, J., & Łuszczki, J. J. (2016). „Endocannabinoid system as a regulator of tumor cell malignancy–biological pathways and clinical significance” (angol nyelven). OncoTargets and therapy9, 4323-36. o. DOI:10.2147/OTT.S106944. PMID27486335.
Scott, K. A., Dalgleish, A. G., & Liu, W. M. (2014). „The Combination of Cannabidiol and Δ9-Tetrahydrocannabinol Enhances the Anticancer Effects of Radiation in an Orthotopic Murine Glioma Model” (angol nyelven). Molecular cancer therapeutics13 (12), 2955-2967. o. DOI:10.1158/1535-7163.MCT-14-0402. PMID25398831.
Borrelli, F., Pagano, E., Romano, B., Panzera, S., Maiello, F., Coppola, D., & Izzo, A. (2014). „Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid” (angol nyelven). Carcinogenesis35 (12), 2787-97. o. DOI:10.1093/carcin/bgu205. PMID25269802.
Galve-Roperh I, Sánchez C, Cortés ML, Gómez del Pulgar T, Izquierdo M, Guzmán M. (2000). „Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation” (angol nyelven). Nature medicine6 (3), 313-319. o. DOI:10.1038/73171. PMID10700234.
Fisher, T., Golan, H., Schiby, G., PriChen, S., Smoum, R., Moshe, I., & Mechoulam, R. (2016). „In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma” (angol nyelven). Current Oncology23 (2), S15. o. DOI:10.3747/co.23.2893. PMID27022310.
Simmerman, E. L., Qin, X., Motamed, K., Jack, C. Y., & Baban, B. (2016). „Determining autophagic activity following cannabidiol treatment of melanoma: a potential new and novel treatment” (angol nyelven). Cancer Research76 (14), Supplement 3544-3544. o. DOI:10.1158/1538-7445.AM2016-3544.
Thomas, AA.,, Wallner, LP., Quinn, VP., Slezak, Van Den Eeden, SK., Chien, GW., Jacobsen, SJ., (2015). „Association between cannabis use and the risk of bladder cancer: results from the California Men's Health Study” (angol nyelven). Urology85 (2), 388-92. o. DOI:10.1016/j.urology.2014.08.060. PMID25623697.
Waissengrin, Barliz, et al. (2015). „Patterns of use of medical cannabis among Israeli cancer patients: A single institution experience” (angol nyelven). Journal of pain and symptom management49 (2), 223-230. o. DOI:10.1016/j.jpainsymman.2014.05.018. PMID24937161.
Aggarwal, S. K. (2016). „Use of cannabinoids in cancer care: palliative care” (angol nyelven). Current Oncology23 (2), S33-6. o. DOI:10.3747/co.23.2962. PMID27022312.
Ananth, P., Ma, C., Al-Sayegh, H., Kroon, L., Klein, V., Wharton, C., London, W. et al. (2017). „Provider Perspectives on Use of Medical Marijuana in Children With Cancer.” (angol nyelven). Pediatrics. DOI:10.1542/peds.2017-0559. PMID29233937.
Zlebnik, N. E., & Cheer, J. F. (2016). „Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?” (angol nyelven). Annual Review of Neuroscience39 (1). DOI:10.1146/annurev-neuro-070815-014038. PMID27023732.
Santos, R. G., Hallak, J. E. C., Leite, J. P., Zuardi, A. W., & Crippa, J. A. S. (2015). „Phytocannabinoids and epilepsy” (angol nyelven). Journal of clinical pharmacy and therapeutics40 (2), 135-143. o. DOI:10.1111/jcpt.12235.
Deiana, S. (2013). „Medical use of cannabis. Cannabidiol: a new light for schizophrenia?” (angol nyelven). Drug testing and analysis5 (1), 46-51. o. DOI:10.1002/dta.1425. PMID23109356.
Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M. L., Muñoz, E., & Sagredo, O. (2015). „Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice” (angol nyelven). Neurotherapeutics12 (1), 185-199. o. DOI:10.1007/s13311-014-0304-z. PMID25252936.
Garay, R. P., Citrome, L., Grossberg, G. T., Cavero, I., & Llorca, P. M. (2016). „Investigational drugs for treating agitation in persons with dementia” (angol nyelven). Expert opinion on investigational drugs1, 973-983. o. DOI:10.1080/13543784.2016.1193155. PMID27232589.
Sagredo, O., Pazos, M. R., Satta, V., Ramos, J. A., Pertwee, R. G., & Fernández‐Ruiz, J. (2011). „Neuroprotective effects of phytocannabinoid‐based medicines in experimental models of Huntington's disease.” (angol nyelven). Journal of neuroscience research89 (9), 1509-1518. o. DOI:10.1002/jnr.22682. PMID21674569.
Di Forti, M., Vassos, E., Lynskey, M., Craig, M., & Murray, R. M. (2015). „Cannabis and psychosis–Authors' reply” (angol nyelven). The Lancet Psychiatry2 (5), 382. o. DOI:10.1016/S2215-0366(15)00177-7. PMID26360275.
Gururajan, A., & Malone, D. T. (2016). „Does cannabidiol have a role in the treatment of schizophrenia?” (angol nyelven). Schizophrenia Research. DOI:10.1016/j.schres.2016.06.022. PMID27374322.
Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE, Crippa JA. (2006). „Cannabidiol monotherapy for treatment-resistant schizophrenia” (angol nyelven). Journal of Psychopharmacology20 (5), 683-686. o. DOI:10.1177/0269881106060967. PMID16401651.
Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JC, Crippa JA, Zuardi AW, Mechoulam R, Guimarães FS. (2016). „Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects” (angol nyelven). PLoS One (Public Library of Science)11 (7), e0158779. o. DOI:10.1371/journal.pone.0158779. PMID27416026.
Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D. (2012). „Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia” (angol nyelven). Translational psychiatry2 (3), e94. o. DOI:10.1038/tp.2012.15. PMID22832859.
Fakhoury M. (2016). „Could cannabidiol be used as an alternative to antipsychotics?” (angol nyelven). Journal of psychiatric research80, 14-21. o. DOI:10.1016/j.jpsychires.2016.05.013. PMID27267317.
Sonego, A. B., Gomes, F. V., Del Bel, E. A., & Guimaraes, F. S. (2016). „Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT 1A receptors in mice” (angol nyelven). Behavioural Brain Research309, 22-28. o. DOI:10.1016/j.bbr.2016.04.042.
Passie, Torsten, et al. (2012). „Mitigation of post‐traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence” (angol nyelven). Drug testing and analysis4 (7-8), 649-659. o. DOI:10.1002/dta.1377. PMID22736575.
Yarnell, S. (2014). „The Use of Medicinal Marijuana for Posttraumatic Stress Disorder: A Review of the Current Literature.” (angol nyelven). The primary care companion for CNS disorders17 (3). DOI:10.4088/PCC.15r01786. PMID26644963.
Verdoux, H., Lagnaoui, R., & Begaud, B. (2005). „Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies” (angol nyelven). Psychological medicine35 (03), 307-315. o. DOI:10.1017/S0033291704003897. PMID15841867.
Petursson, H., & Lader, M. H. (1981). „Withdrawal from long-term benzodiazepine treatment” (angol nyelven). Br Med J (Clin Res Ed)283 (6292), 643-645. o. DOI:10.1136/bmj.283.6292.643.
Russo, E. B., Guy, G. W., & Robson, P. J. (2007). „Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a Cannabis‐Based Medicine” (angol nyelven). Chemistry & biodiversity4 (6), 1729-1743. o. DOI:10.1002/cbdv.200790150.
El-Alfy, A. T., Ivey, K., Robinson, K., Ahmed, S., Radwan, M., Slade, D., & Ross, S. (2010). „Antidepressant-like effect of Δ 9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.” (angol nyelven). Pharmacology Biochemistry and Behavior95 (4), 434-442. o. DOI:10.1016/j.pbb.2010.03.004.
Kuhlen, M., Hoell, J. I., Gagnon, G., Balzer, S., Oommen, P. T., Borkhardt, A., & Janßen, G. (2016). „Effective treatment of spasticity using dronabinol in pediatric palliative care” (angol nyelven). European Journal of Paediatric Neurology16. DOI:10.1016/j.ejpn.2016.07.021. PMID27506815.
Kral, A. H., Wenger, L., Novak, S. P., Chu, D., Corsi, K. F., Coffa, D., & Bluthenthal, R. N (2015). „Is Cannabis use associated with less opioid use among people who inject drugs?” (angol nyelven). Drug and Alcohol Dependence153, 236-241. o. DOI:10.1016/j.drugalcdep.2015.05.014. PMID26051162.
Morgan, Celia JA, et al. (2013). „Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings” (angol nyelven). Addictive behaviors38 (9), 2433-2436. o. DOI:10.1016/j.addbeh.2013.03.011. PMID23685330.
Carlo, G. D., & Izzo, A. A. (2003). „Cannabinoids for gastrointestinal diseases: potential therapeutic applications” (angol nyelven). Expert opinion on investigational drugs12 (1), 39-49. o. DOI:10.1517/13543784.12.1.39.
Goyal, H., Singla, U., Gupta, U., & May, E. (2016). „Role of cannabis in digestive disorders.” (angol nyelven). European journal of gastroenterology & hepatology. DOI:10.1097/MEG.0000000000000779. PMID27792038.
Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. (2013). „Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study” (angol nyelven). Clinical Gastroenterology and Hepatology11 (10), 1276-1280. o. DOI:10.1016/j.cgh.2013.04.034. PMID23648372.
Vu MP, Melmed GY, Targan SR. (2014). „Weeding Out the Facts: The Reality About Cannabis and Crohn's Disease” (angol nyelven). Clinical Gastroenterology and Hepatology12 (5), 898-899. o. DOI:10.1016/j.cgh.2013.11.016. PMID24269921.
Borrelli, F., Fasolino, I., Romano, B., Capasso, R., Maiello, F., Coppola, D., & Izzo, A. A. (2013). „Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease” (angol nyelven). Biochemical pharmacology85 (9), 1306-1316. o. DOI:10.1016/j.bcp.2013.01.017. PMID23415610.
Ngueta G, Bélanger RE, Laouan-Sidi EA, Lucas M. (2015). „Cannabis use in relation to obesity and insulin resistance in the inuit population” (angol nyelven). Obesity23 (2), 290-295. o. DOI:10.1002/oby.20973.. PMID25557382.
Kim, D., Kim, W., Kwak, M. S., Chung, G. E., Yim, J. Y., & Ahmed, A. (2017). „Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States.” (angol nyelven). PloS one12 (10). DOI:10.1371/journal.pone.0186702. PMID29049354.
Comelli F, Bettoni I, Colleoni M, Giagnoni G, Costa B. (2009). „Beneficial effects of a Cannabis sativa extract treatment on diabetes‐induced neuropathy and oxidative stress” (angol nyelven). Phytotherapy research23 (12), 1678-1684. o. DOI:10.1002/ptr.2806. PMID19441010.
Harris, H. M., Sufka, K. J., Gul, W., & ElSohly, M. A. (2016). „Effects of Delta-9-Tetrahydrocannabinol and Cannabidiol on Cisplatin-Induced Neuropathy in Mice” (angol nyelven). Planta medica82 (13), 1169-72. o. DOI:0.1055/s-0042-106303. PMID27214593.
Rajavashisth TB, Shaheen M, Norris KC, Pan D, Sinha SK, Ortega J, Friedman TC. (2012). „Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey” (angol nyelven). BMJ open2 (1). DOI:10.1136/bmjopen-2011-000494. PMID22368296.
Yazulla S. (2008). „Endocannabinoids in the retina: from marijuana to neuroprotection” (angol nyelven). Progress in retinal and eye research (Review)27 (5), 501–26. o. DOI:10.1016/j.preteyeres.2008.07.002. PMID18725316.
Samudre, S., Hosseini, A., & Lattanzio, F. (2014). „Cannabinoids: a novel treatment for glaucoma” (angol nyelven). Acta Ophthalmologica92. DOI:10.1111/j.1755-3768.2014.T022.x.
Panahi, Y., Manayi, A., Nikan, M., & Vazirian, M. (2017). „The arguments for and against cannabinoids application in glaucomatous retinopathy” (angol nyelven). Biomedicine & Pharmacotherapy86, 620-627. o. DOI:10.1016/j.biopha.2016.11.106. PMID28027538.
Lanz, C., Mattsson, J., Soydaner, U., & Brenneisen, R. (2016). „Medicinal cannabis: in vitro validation of vaporizers for the smoke-free inhalation of cannabis.” (angol nyelven). PloS one11 (1). DOI:10.1371/journal.pone.0147286. PMID26784441.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002). „Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study” (angol nyelven). BMJ325 (7374), 1212–1213. o. DOI:10.1136/bmj.325.7374.1212.
Danielsson, Anna-Karin, et al. (2016). „Cannabis use, depression and anxiety: A 3-year prospective population-based study” (angol nyelven). Journal of affective disorders193, 103–108. o. DOI:10.1016/j.jad.2015.12.045. PMID26773900.
Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E (2016). „Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis” (angol nyelven). Schizophrenia bulletin, sbw003. o. DOI:10.1093/schbul/sbw003. PMID26884547.
Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., & Butt, A. et al. (2009). „High-potency cannabis and the risk of psychosis” (angol nyelven). The British Journal of Psychiatry195 (6), 488–491. o. DOI:10.1192/bjp.bp.109.064220.
Kuepper, R., van Os, J., Lieb, R., Wittchen, H. U., Höfler, M., & Henquet, C. (2011). „Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study.” (angol nyelven). Bmj (342), d738. o. DOI:10.1136/bmj.d738. PMID21363868.
Feingold D, Weiser M, Rehm J, Lev-Ran S. (2015). „The association between cannabis use and mood disorders: A longitudinal study” (angol nyelven). Journal of affective disorders1 (172), 211–218. o. DOI:10.1016/j.jad.2014.10.006. PMID25451420.
Ksir, Charles, and Carl L. Hart (2016). „Cannabis and psychosis: a critical overview of the relationship” (angol nyelven). Current psychiatry reports18 (2), 1–11). o. DOI:10.1007/s11920-015-0657-y. PMID26781550.
Rohde, P., Lewinsohn, P. M., & Seeley, J. R. (1996). „[Psychiatric comorbidity with problematic alcohol use in high school students Psychiatric comorbidity with problematic alcohol use in high school students.]” (angol nyelven). Journal of the American Academy of Child & Adolescent Psychiatry35 (1), 101–109. o. DOI:10.1097/00004583-199601000-00018. PMID8567601.
Schwartz, R. H., Gruenewald, P. J., Klitzner, M., & Fedio, P. (1989). „Short-term memory impairment in cannabis-dependent adolescents” (angol nyelven). American Journal of Diseases of Children143 (10), 1214–1219. o. DOI:10.1001/archpedi.1989.02150220110030.. PMID2801665.
Curran, V. H., Brignell, C., Fletcher, S., Middleton, P., & Henry, J. (2002). „Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.” (angol nyelven). Psychopharmacology64 (1), 61–70. o. DOI:10.1007/s00213-002-1169-0. PMID12373420.
Nafea, O. E., ElKhishin, I. A., Awad, O. A., & Mohamed, D. A. (2016). „A study of the neurotoxic effects of tramadol and cannabis in adolescent male albino rats” (angol nyelven). International Journal of Scientific Reports2 (7), 143–154. o. DOI:10.18203/issn.2454-2156.IntJSciRep20162164.
Hall, W., & Lynskey, M. (2016). „Long-term Marijuana Use and Cognitive Impairment in Middle Age.” (angol nyelven). JAMA internal medicine176 (3), 362–363. o. DOI:10.1001/jamainternmed.2015.7850. PMID26830958.
Filbey, F. M., Aslan, S., Calhoun, V. D., Spence, J. S., Damaraju, E., Caprihan, A., & Segall, J (2014). „Long-term effects of marijuana use on the brain.” (angol nyelven). Proceedings of the National Academy of Sciences111 (47), 16913–16918. o. DOI:10.1073/pnas.1415297111.
Bilkei-Gorzo, A., Albayram, O., Draffehn, A., Michel, K., Piyanova, A., Oppenheimer, H., ... & Bab, I. (2017). „A chronic low dose of [Delta] 9-tetrahydrocannabinol (THC) restores cognitive function in old mice.” (angol nyelven). Nature Medicine (23), 782–787. o. DOI:10.1038/nm.4311. PMID28481360.
Mathalone, N., A. Wolf, and O. Geyer. (2015). „Cannabis and claucoma” (angol nyelven). Israel Medical Association "Harefuah"154 (6), 394-7. o. PMID26281086.
Marijuana Policy Project: State Policy (angol nyelven). MPP. [2016. augusztus 5-i dátummal az eredetiből archiválva]. (Hozzáférés: 2016. szeptember 1.)
Simon Zoltan: Történelmi voksolás a fűről (magyar nyelven). Népszava online, 2016. december 17. [2017. január 1-i dátummal az eredetiből archiválva]. (Hozzáférés: 2016. december 31.)
Népszava: Marihuána, orvosi receptre. NSZO, 2016. június 2. [2017. február 4-i dátummal az eredetiből archiválva]. (Hozzáférés: 2017. február 3.)
Aizpurua-Olaizola, O., Soydaner, U., Öztürk, E., Schibano, D., Simsir, Y., Navarro, P., et al. & Usobiaga, A. (2016). „Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes” (angol nyelven). Journal of natural products79 (2), 324–331. o. DOI:10.1021/acs.jnatprod.5b00949. PMID26836472.
Chan PC, Sills RC, Braun AG, Haseman JK, Bucher JR. (1996). „Toxicity and carcinogenicity of Δ9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice.” (angol nyelven). Toxicological Sciences30 (1), 109-117. o. PMID8812248.
Sánchez C, Galve-Roperh I, Canova C, Brachet P, Guzmán M. (1998). „Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells.” (angol nyelven). Journal of the National Cancer Institute436 (1), 6-10. o. PMID9771884.
Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, Sánchez C, Velasco G, González-Feria L. (2006). „A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme” (angol nyelven). British journal of cancer95 (2), 197-203. o. DOI:10.1038/sj.bjc.6603236. PMID16804518.
Grbic, J., Goddard, P., & Ryder, D. (2017). „Observations of the role of science in the United States medical cannabis state policies: Lessons learnt” (angol nyelven). International Journal of Drug Policy. DOI:10.1016/j.drugpo.2016.12.019. PMID28190671.
Hussain, S. A., Zhou, R., Jacobson, C., Weng, J., Cheng, E., Lay, J., & Sankar, R. (2015). „Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox–Gastaut syndrome.” (angol nyelven). Epilepsy & Behavior47, 138-41.. o. DOI:10.1016/j.yebeh.2015.04.009. PMID25935511.
Silvestro, S., Mammana, S., Cavalli, E., Bramanti, P., & Mazzon, E. (2019). „Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials” (angol nyelven) 24 (8). DOI:10.3390/molecules24081459. PMID31013866.
Pacula, Rosalie Liccardo, et al. (2014). „Developing public health regulations for marijuana: lessons from alcohol and tobacco” (angol nyelven). Journal Information104 (6), 1021-8.. o. DOI:10.2105/AJPH.2013.301766. PMID24825201.
Calabria, B., Degenhardt, L., Hall, W., & Lynskey, M. (2010). „Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use” (angol nyelven). Drug and alcohol review29 (3), 318-330. o. DOI:10.1111/j.1465-3362.2009.00149.x. PMID20565525.
Thomas, Hue. (1993). „Psychiatric symptoms in cannabis users” (angol nyelven). The British Journal of Psychiatry163 (2), 141-149. o. DOI:10.1192/bjp.163.2.141. PMID8075903.
Laumon, B., Gadegbeku, B., Martin, J. L., & Biecheler, M. B. (2005). „Cannabis intoxication and fatal road crashes in France: population based case-control study” (angol nyelven). Bmj331 (7529), 1371. o. DOI:10.1136/bmj.38648.617986.1F. PMID16321993.
Hesse M., Thylstrup B. (2013). „Time-course of the DSM-5 cannabis withdrawal symptoms in poly-substance abusers” (angol nyelven). BMC psychiatry13 (1), 1. o. DOI:10.1186/1471-244X-13-258. PMID24118963.
Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D. (2013). „The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users” (angol nyelven). Drug and alcohol dependence128 (1), 64-70. o. DOI:10.1016/j.drugalcdep.2012.08.001. PMID22921474.
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., et al. & UK MS research group. (2003). „Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.” (angol nyelven). Lancet362 (9395), 1517-1526. o. DOI:10.1016/S0140-6736(03)14738-1. PMID14615106.
Makela P, Robson P, House H, Bateman C. (2004). „Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.” (angol nyelven). Multiple Sclerosis10 (4), 434-441. o. DOI:10.1191/1352458504ms1082oa. PMID15327042.
Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ. (2005). „Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.” (angol nyelven). J. Neurol. Neurosurg. Psychiatry76 (12), 1664--1669. o. DOI:10.1136/jnnp.2005.070136. PMID16291891.
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., et al. & Rossi, P. (2011). „A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols*(Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis.” (angol nyelven). European Journal of Neurology18 (9), 1122–1131. o. DOI:10.1111/j.1468-1331.2010.03328.x. PMID21362108.
Koppel, B. S., Brust, J. C., Fife, T., Bronstein, J., Youssof, S., Gronseth, G., & Gloss, D. (2014. April). „Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders” (angol nyelven). Neurology82 (17), 1556-1563. o. DOI:10.1212/WNL.0000000000000363.. PMID24778283.
Iskedjian, M., Bereza, B., Gordon, A., Piwko, C., & Einarson, T. R. (2007). „Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.” (angol nyelven). Current medical research and opinion23 (1), 17-24. o. DOI:10.1185/030079906X158066. PMID17257464.
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005). „Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.” (angol nyelven). Neurology65 (6), 812-819. o. DOI:10.1212/01.wnl.0000176753.45410.8b. PMID16186518.
Rog, David J., Turo J. Nurmikko, and Carolyn A. Young. (2007). „Oromucosal Δ 9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.” (angol nyelven). Clinical therapeutics29 (9), 2068-2079. o. DOI:10.1016/j.clinthera.2007.09.013. PMID18035205.
Serpell, Michael G., William Notcutt, and Christine Collin. (2013). „Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.” (angol nyelven). Journal of neurology260 (1), 285-295. o. DOI:10.1007/s00415-012-6634-z. PMID22878432.
Haupts, M., Vila, C., Jonas, A., Witte, K., & Álvarez-Ossorio, L. (2016). „Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC: CBD Oromucosal Spray for Multiple Sclerosis Spasticity.” (angol nyelven). European Neurology75 (5-6), 236-243. o. DOI:10.1159/000445943. PMID27160412.
Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D. (2015). „Neuroprotection in experimental autoimmune encephalomyelitis and progressive multiple sclerosis by cannabis-based cannabinoids.” (angol nyelven). Journal of Neuroimmune Pharmacology10 (2), 281-292. o. DOI:10.1007/s11481-014-9575-8. PMID25537576.
Brady, C. M., DasGupta, R., Dalton, C., Wiseman, O. J., Berkley, K. J., & Fowler, C. J. (2004). „An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.” (angol nyelven). Multiple Sclerosis10 (4), 425-433. o. DOI:10.1191/1352458504ms1063oa. PMID15327041.
Kavia, R. B. C., De Ridder, D., Constantinescu, C. S., Stott, C. G., & Fowler, C. J. (2010). „Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.” (angol nyelven). Multiple Sclerosis16 (11), 1349-1359. o. DOI:10.1177/1352458510378020. PMID20829244.
Mecha, M., Feliú, A., Iñigo, P. M., Mestre, L., Carrillo-Salinas, F. J., & Guaza, C. (2013). „Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A 2A receptors.” (angol nyelven). Neurobiology of disease (59), 141-150. o. DOI:10.1016/j.nbd.2013.06.016. PMID23851307.
Granja, A. G., Carrillo-Salinas, F., Pagani, A., Gómez-Cañas, M., Negri, R., Navarrete, C., Calzado, M. A. (2012). „A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis.” (angol nyelven). Journal of Neuroimmune Pharmacology7 (4), 1002-1016.. o. DOI:10.1007/s11481-012-9399-3. PMID22971837.
Giacoppo, S., Rajan, T. S., Galuppo, M., Pollastro, F., Grassi, G., Bramanti, P., & Mazzon, E. (2015). „Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis.” (angol nyelven). European review for medical and pharmacological sciences19 (24), 4906-4919. o. PMID26744883.
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., & Wong, M. (2016). „Cannabidiol for Intractable Epilepsy: Results from the Latest Open-Label Trial” (angol nyelven). The Lancet Neurology15 (3), 270-278.. o. DOI:10.1016/S1474-4422(15)00379-8. PMID26724101.
Gross DW, Hamm J, Ashworth NL, Quigley D. (2014). „Marijuana use and epilepsy Prevalence in patients of a tertiary care epilepsy center” (angol nyelven). Neurology62 (11), 2095-2097.. o. DOI:10.1212/01.WNL.0000127623.03766.75. PMID15184622.
Mao, K., You, C., Lei, D., & Zhang, H. (2015). „High dosage of cannabidiol (CBD) alleviates pentylenetetrazole-induced epilepsy in rats by exerting an anticonvulsive effect” (angol nyelven). International journal of clinical and experimental medicine8, 8820.. o. PMID26309534.
Mathern GW, Beninsig L, Nehlig A. (2015). „Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: Result of Epilepsia's survey” (angol nyelven). Epilepsia56 (1), 1-6. o. DOI:10.1111/epi.12843. PMID25413126.
Alexander SP (2016). „Therapeutic potential of cannabis-related drugs” (angol nyelven). Progress in Neuro-Psychopharmacology and Biological Psychiatry4 (64), 157-166. o. DOI:10.1016/j.pnpbp.2015.07.001. PMID26216862.
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., et al. & Wong, M. (2016). „Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial” (angol nyelven). The Lancet Neurology15 (3), 270-278. o. DOI:10.1016/S1474-4422(15)00379-8. PMID26724101.
Borgelt LM, Franson KL, Nussbaum AM, Wang GS (2013). „The pharmacologic and clinical effects of medical cannabis” (angol nyelven). Pharmacotherapy (Review)33 (2), 195–209. o. DOI:10.1002/phar.1187.. PMID23386598.
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006). „The emerging role of the endocannabinoid system in endocrine regulation and energy balance.” (angol nyelven). Endocrine reviews27 (1), 73-100. o. DOI:10.1210/er.2005-0009. PMID16306385.
Charlson, Fiona, et al. (2009). „A systematic review of research examining benzodiazepine‐related mortality” (angol nyelven). Pharmacoepidemiology and drug safety18 (2), 93-103.. o. DOI:10.1002/pds.1694. PMID19125401.
Bowles, DW (2012. január 6.). „The intersection between cannabis and cancer in the United States”. Critical reviews in oncology/hematology83 (1), 1–10. o. DOI:10.1016/j.critrevonc.2011.09.008. PMID22019199.
Abrams, D. I. (2016). „Integrating cannabis into clinical cancer care” (angol nyelven). Current Oncology23 (2), S8. o. DOI:10.3747/co.23.3099. PMID27022315.
Pyszniak, M., Tabarkiewicz, J., & Łuszczki, J. J. (2016). „Endocannabinoid system as a regulator of tumor cell malignancy–biological pathways and clinical significance” (angol nyelven). OncoTargets and therapy9, 4323-36. o. DOI:10.2147/OTT.S106944. PMID27486335.
Scott, K. A., Dalgleish, A. G., & Liu, W. M. (2014). „The Combination of Cannabidiol and Δ9-Tetrahydrocannabinol Enhances the Anticancer Effects of Radiation in an Orthotopic Murine Glioma Model” (angol nyelven). Molecular cancer therapeutics13 (12), 2955-2967. o. DOI:10.1158/1535-7163.MCT-14-0402. PMID25398831.
Borrelli, F., Pagano, E., Romano, B., Panzera, S., Maiello, F., Coppola, D., & Izzo, A. (2014). „Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid” (angol nyelven). Carcinogenesis35 (12), 2787-97. o. DOI:10.1093/carcin/bgu205. PMID25269802.
Galve-Roperh I, Sánchez C, Cortés ML, Gómez del Pulgar T, Izquierdo M, Guzmán M. (2000). „Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation” (angol nyelven). Nature medicine6 (3), 313-319. o. DOI:10.1038/73171. PMID10700234.
Fisher, T., Golan, H., Schiby, G., PriChen, S., Smoum, R., Moshe, I., & Mechoulam, R. (2016). „In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma” (angol nyelven). Current Oncology23 (2), S15. o. DOI:10.3747/co.23.2893. PMID27022310.
Thomas, AA.,, Wallner, LP., Quinn, VP., Slezak, Van Den Eeden, SK., Chien, GW., Jacobsen, SJ., (2015). „Association between cannabis use and the risk of bladder cancer: results from the California Men's Health Study” (angol nyelven). Urology85 (2), 388-92. o. DOI:10.1016/j.urology.2014.08.060. PMID25623697.
Waissengrin, Barliz, et al. (2015). „Patterns of use of medical cannabis among Israeli cancer patients: A single institution experience” (angol nyelven). Journal of pain and symptom management49 (2), 223-230. o. DOI:10.1016/j.jpainsymman.2014.05.018. PMID24937161.
Aggarwal, S. K. (2016). „Use of cannabinoids in cancer care: palliative care” (angol nyelven). Current Oncology23 (2), S33-6. o. DOI:10.3747/co.23.2962. PMID27022312.
Ananth, P., Ma, C., Al-Sayegh, H., Kroon, L., Klein, V., Wharton, C., London, W. et al. (2017). „Provider Perspectives on Use of Medical Marijuana in Children With Cancer.” (angol nyelven). Pediatrics. DOI:10.1542/peds.2017-0559. PMID29233937.
Zlebnik, N. E., & Cheer, J. F. (2016). „Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?” (angol nyelven). Annual Review of Neuroscience39 (1). DOI:10.1146/annurev-neuro-070815-014038. PMID27023732.
Deiana, S. (2013). „Medical use of cannabis. Cannabidiol: a new light for schizophrenia?” (angol nyelven). Drug testing and analysis5 (1), 46-51. o. DOI:10.1002/dta.1425. PMID23109356.
Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M. L., Muñoz, E., & Sagredo, O. (2015). „Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice” (angol nyelven). Neurotherapeutics12 (1), 185-199. o. DOI:10.1007/s13311-014-0304-z. PMID25252936.
Garay, R. P., Citrome, L., Grossberg, G. T., Cavero, I., & Llorca, P. M. (2016). „Investigational drugs for treating agitation in persons with dementia” (angol nyelven). Expert opinion on investigational drugs1, 973-983. o. DOI:10.1080/13543784.2016.1193155. PMID27232589.
Sagredo, O., Pazos, M. R., Satta, V., Ramos, J. A., Pertwee, R. G., & Fernández‐Ruiz, J. (2011). „Neuroprotective effects of phytocannabinoid‐based medicines in experimental models of Huntington's disease.” (angol nyelven). Journal of neuroscience research89 (9), 1509-1518. o. DOI:10.1002/jnr.22682. PMID21674569.
Di Forti, M., Vassos, E., Lynskey, M., Craig, M., & Murray, R. M. (2015). „Cannabis and psychosis–Authors' reply” (angol nyelven). The Lancet Psychiatry2 (5), 382. o. DOI:10.1016/S2215-0366(15)00177-7. PMID26360275.
Gururajan, A., & Malone, D. T. (2016). „Does cannabidiol have a role in the treatment of schizophrenia?” (angol nyelven). Schizophrenia Research. DOI:10.1016/j.schres.2016.06.022. PMID27374322.
Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE, Crippa JA. (2006). „Cannabidiol monotherapy for treatment-resistant schizophrenia” (angol nyelven). Journal of Psychopharmacology20 (5), 683-686. o. DOI:10.1177/0269881106060967. PMID16401651.
Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JC, Crippa JA, Zuardi AW, Mechoulam R, Guimarães FS. (2016). „Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects” (angol nyelven). PLoS One (Public Library of Science)11 (7), e0158779. o. DOI:10.1371/journal.pone.0158779. PMID27416026.
Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D. (2012). „Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia” (angol nyelven). Translational psychiatry2 (3), e94. o. DOI:10.1038/tp.2012.15. PMID22832859.
Fakhoury M. (2016). „Could cannabidiol be used as an alternative to antipsychotics?” (angol nyelven). Journal of psychiatric research80, 14-21. o. DOI:10.1016/j.jpsychires.2016.05.013. PMID27267317.
Passie, Torsten, et al. (2012). „Mitigation of post‐traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence” (angol nyelven). Drug testing and analysis4 (7-8), 649-659. o. DOI:10.1002/dta.1377. PMID22736575.
Yarnell, S. (2014). „The Use of Medicinal Marijuana for Posttraumatic Stress Disorder: A Review of the Current Literature.” (angol nyelven). The primary care companion for CNS disorders17 (3). DOI:10.4088/PCC.15r01786. PMID26644963.
Verdoux, H., Lagnaoui, R., & Begaud, B. (2005). „Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies” (angol nyelven). Psychological medicine35 (03), 307-315. o. DOI:10.1017/S0033291704003897. PMID15841867.
Kuhlen, M., Hoell, J. I., Gagnon, G., Balzer, S., Oommen, P. T., Borkhardt, A., & Janßen, G. (2016). „Effective treatment of spasticity using dronabinol in pediatric palliative care” (angol nyelven). European Journal of Paediatric Neurology16. DOI:10.1016/j.ejpn.2016.07.021. PMID27506815.
Kral, A. H., Wenger, L., Novak, S. P., Chu, D., Corsi, K. F., Coffa, D., & Bluthenthal, R. N (2015). „Is Cannabis use associated with less opioid use among people who inject drugs?” (angol nyelven). Drug and Alcohol Dependence153, 236-241. o. DOI:10.1016/j.drugalcdep.2015.05.014. PMID26051162.
Morgan, Celia JA, et al. (2013). „Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings” (angol nyelven). Addictive behaviors38 (9), 2433-2436. o. DOI:10.1016/j.addbeh.2013.03.011. PMID23685330.
Goyal, H., Singla, U., Gupta, U., & May, E. (2016). „Role of cannabis in digestive disorders.” (angol nyelven). European journal of gastroenterology & hepatology. DOI:10.1097/MEG.0000000000000779. PMID27792038.
Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. (2013). „Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study” (angol nyelven). Clinical Gastroenterology and Hepatology11 (10), 1276-1280. o. DOI:10.1016/j.cgh.2013.04.034. PMID23648372.
Vu MP, Melmed GY, Targan SR. (2014). „Weeding Out the Facts: The Reality About Cannabis and Crohn's Disease” (angol nyelven). Clinical Gastroenterology and Hepatology12 (5), 898-899. o. DOI:10.1016/j.cgh.2013.11.016. PMID24269921.
Borrelli, F., Fasolino, I., Romano, B., Capasso, R., Maiello, F., Coppola, D., & Izzo, A. A. (2013). „Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease” (angol nyelven). Biochemical pharmacology85 (9), 1306-1316. o. DOI:10.1016/j.bcp.2013.01.017. PMID23415610.
Ngueta G, Bélanger RE, Laouan-Sidi EA, Lucas M. (2015). „Cannabis use in relation to obesity and insulin resistance in the inuit population” (angol nyelven). Obesity23 (2), 290-295. o. DOI:10.1002/oby.20973.. PMID25557382.
Kim, D., Kim, W., Kwak, M. S., Chung, G. E., Yim, J. Y., & Ahmed, A. (2017). „Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States.” (angol nyelven). PloS one12 (10). DOI:10.1371/journal.pone.0186702. PMID29049354.
Comelli F, Bettoni I, Colleoni M, Giagnoni G, Costa B. (2009). „Beneficial effects of a Cannabis sativa extract treatment on diabetes‐induced neuropathy and oxidative stress” (angol nyelven). Phytotherapy research23 (12), 1678-1684. o. DOI:10.1002/ptr.2806. PMID19441010.
Harris, H. M., Sufka, K. J., Gul, W., & ElSohly, M. A. (2016). „Effects of Delta-9-Tetrahydrocannabinol and Cannabidiol on Cisplatin-Induced Neuropathy in Mice” (angol nyelven). Planta medica82 (13), 1169-72. o. DOI:0.1055/s-0042-106303. PMID27214593.
Rajavashisth TB, Shaheen M, Norris KC, Pan D, Sinha SK, Ortega J, Friedman TC. (2012). „Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey” (angol nyelven). BMJ open2 (1). DOI:10.1136/bmjopen-2011-000494. PMID22368296.
Yazulla S. (2008). „Endocannabinoids in the retina: from marijuana to neuroprotection” (angol nyelven). Progress in retinal and eye research (Review)27 (5), 501–26. o. DOI:10.1016/j.preteyeres.2008.07.002. PMID18725316.
Mathalone, N., A. Wolf, and O. Geyer. (2015). „Cannabis and claucoma” (angol nyelven). Israel Medical Association "Harefuah"154 (6), 394-7. o. PMID26281086.
Panahi, Y., Manayi, A., Nikan, M., & Vazirian, M. (2017). „The arguments for and against cannabinoids application in glaucomatous retinopathy” (angol nyelven). Biomedicine & Pharmacotherapy86, 620-627. o. DOI:10.1016/j.biopha.2016.11.106. PMID28027538.
Lanz, C., Mattsson, J., Soydaner, U., & Brenneisen, R. (2016). „Medicinal cannabis: in vitro validation of vaporizers for the smoke-free inhalation of cannabis.” (angol nyelven). PloS one11 (1). DOI:10.1371/journal.pone.0147286. PMID26784441.
Huizink, A.C. and Mulder, E.J. (2006). „Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring” (angol nyelven). Neuroscience & Biobehavioral Reviews30 (1), 24–41. o. PMID16095697.
Fried PA, Watkinson B, Gray R. (2003). „Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana” (angol nyelven). Neurotoxicology and teratology25 (4), 427–436. o. PMID12798960.
Danielsson, Anna-Karin, et al. (2016). „Cannabis use, depression and anxiety: A 3-year prospective population-based study” (angol nyelven). Journal of affective disorders193, 103–108. o. DOI:10.1016/j.jad.2015.12.045. PMID26773900.
Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E (2016). „Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis” (angol nyelven). Schizophrenia bulletin, sbw003. o. DOI:10.1093/schbul/sbw003. PMID26884547.
Kuepper, R., van Os, J., Lieb, R., Wittchen, H. U., Höfler, M., & Henquet, C. (2011). „Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study.” (angol nyelven). Bmj (342), d738. o. DOI:10.1136/bmj.d738. PMID21363868.
Feingold D, Weiser M, Rehm J, Lev-Ran S. (2015). „The association between cannabis use and mood disorders: A longitudinal study” (angol nyelven). Journal of affective disorders1 (172), 211–218. o. DOI:10.1016/j.jad.2014.10.006. PMID25451420.
Ksir, Charles, and Carl L. Hart (2016). „Cannabis and psychosis: a critical overview of the relationship” (angol nyelven). Current psychiatry reports18 (2), 1–11). o. DOI:10.1007/s11920-015-0657-y. PMID26781550.
Rohde, P., Lewinsohn, P. M., & Seeley, J. R. (1996). „[Psychiatric comorbidity with problematic alcohol use in high school students Psychiatric comorbidity with problematic alcohol use in high school students.]” (angol nyelven). Journal of the American Academy of Child & Adolescent Psychiatry35 (1), 101–109. o. DOI:10.1097/00004583-199601000-00018. PMID8567601.
Schwartz, R. H., Gruenewald, P. J., Klitzner, M., & Fedio, P. (1989). „Short-term memory impairment in cannabis-dependent adolescents” (angol nyelven). American Journal of Diseases of Children143 (10), 1214–1219. o. DOI:10.1001/archpedi.1989.02150220110030.. PMID2801665.
Curran, V. H., Brignell, C., Fletcher, S., Middleton, P., & Henry, J. (2002). „Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.” (angol nyelven). Psychopharmacology64 (1), 61–70. o. DOI:10.1007/s00213-002-1169-0. PMID12373420.
Fried P, Watkinson B, James D, Gray R. (2002). „Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults” (angol nyelven). Canadian Medical Association Journal166 (7), 887–891. o. PMID11949984.
Chan GC, Hinds TR, Impey S, Storm DR. (1998). „Hippocampal Neurotoxicity of Delta 9-Tetrahydrocannabinol” (angol nyelven). Journal of Neuroscience18 (14), 5322. o. PMID9651215.
Hall, W., & Lynskey, M. (2016). „Long-term Marijuana Use and Cognitive Impairment in Middle Age.” (angol nyelven). JAMA internal medicine176 (3), 362–363. o. DOI:10.1001/jamainternmed.2015.7850. PMID26830958.
Wert, R. C., & Raulin, M. L. (1986). „The chronic cerebral effects of cannabis use. I. Methodological issues and neurological findings” (angol nyelven). Substance Use & Misuse21 (6), 605–628. o. PMID3017872.
Bilkei-Gorzo, A., Albayram, O., Draffehn, A., Michel, K., Piyanova, A., Oppenheimer, H., ... & Bab, I. (2017). „A chronic low dose of [Delta] 9-tetrahydrocannabinol (THC) restores cognitive function in old mice.” (angol nyelven). Nature Medicine (23), 782–787. o. DOI:10.1038/nm.4311. PMID28481360.
Varga, Z., rafay ali Sabzwari, S., & Vargova, V. (2017). „Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue” (angol nyelven). Cureus9 (4). DOI:10.7759/cureus.1144. PMC5422108.
Sansone, R. A., & Sansone, L. A. (2014). „Marijuana and Body Weight” (angol nyelven). Innovations in clinical neuroscience11 (7/8), 50-54. o. PMC4204468.
Füves filmek legjobb jelenetei (magyar nyelven). Offline.hu, 2014. április 17. [2016. szeptember 16-i dátummal az eredetiből archiválva]. (Hozzáférés: 2016. szeptember 4.)
Paul Berghius, Ann M Rajnicek, Yury M Morozov, Ruth A Ross, Jan Mulder, Gabriella M Urbán, Krisztina Monory, Giovanni Marsicano, Michela Matteoli, Alison Canty, Andrew J Irving, István Katona et al.: Hardwiring the Brain: Endocannabinoids Shape Neuronal Connectivity Science (angol nyelven). sciencedaily.com, 2007. május 25. (Hozzáférés: 2016. szeptember 4.)
Semmelweis Egyetem: Kannabidiol a metabolikus szindróma ellen (magyar nyelven). Semmelweis Figyelő, 2013. június 27. [2016. augusztus 29-i dátummal az eredetiből archiválva]. (Hozzáférés: 2016. szeptember 4.)
Marijuana Policy Project: State Policy (angol nyelven). MPP. [2016. augusztus 5-i dátummal az eredetiből archiválva]. (Hozzáférés: 2016. szeptember 1.)
Simon Zoltan: Történelmi voksolás a fűről (magyar nyelven). Népszava online, 2016. december 17. [2017. január 1-i dátummal az eredetiből archiválva]. (Hozzáférés: 2016. december 31.)
Semmelweis Egyetem: Kannabidiol a metabolikus szindróma ellen (magyar nyelven). Semmelweis Figyelő, 2013. június 27. [2016. augusztus 29-i dátummal az eredetiből archiválva]. (Hozzáférés: 2016. szeptember 4.)
EMCDDA Cannabis readerArchiválva2014. október 27-i dátummal a Wayback Machine-ben: Global issues and local experiences, Perspectives on Cannabis controversies, treatment and regulation in Europe, 2008, p. 157.
Füves filmek legjobb jelenetei (magyar nyelven). Offline.hu, 2014. április 17. [2016. szeptember 16-i dátummal az eredetiből archiválva]. (Hozzáférés: 2016. szeptember 4.)
Santos, R. G., Hallak, J. E. C., Leite, J. P., Zuardi, A. W., & Crippa, J. A. S. (2015). „Phytocannabinoids and epilepsy” (angol nyelven). Journal of clinical pharmacy and therapeutics40 (2), 135-143. o. DOI:10.1111/jcpt.12235.
EMCDDA Cannabis readerArchiválva2014. október 27-i dátummal a Wayback Machine-ben: Global issues and local experiences, Perspectives on Cannabis controversies, treatment and regulation in Europe, 2008, p. 157.
